Overview

Collagenase Option for Reduction of Dupuytren's Contracture in Japan

Status:
Completed
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
To investigate the efficacy and safety of AK160 in patients with Dupuytren's Contracture. To determine plasma concentration after the first injection of AK160 in patients with Dupuytren's Contracture.
Phase:
Phase 3
Details
Lead Sponsor:
Asahi Kasei Pharma Corporation